A prospective, comparative, randomized trial to evaluate the clinical efficacy and safety of Shudhhi Vati (ayurvedic drug) in comparison with Lactulose (allopathic drug) in children suffering from chronic constipation
试验速览
- 阶段
- Phase 3 4
- 状态
- 尚未招募
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Average change in passing Frequency & consistency of stool
研究概览
简要总结
This will be A prospective, comparative, randomized trial to evaluate the clinical efficacy and safety of Shudhhi Vati (ayurvedic drug) in comparison with Lactulose (allopathic drug) in children suffering from chronic constipation.
**AIM AND OBJECTIVES:**1. Increase quality of life & daily activity of children. 2. Decrease episodes of constipation.
MATERIAL AND METHODS:
**STUDY DESIGN:**A Prospective, Randomized, Two arm, parallel, hospital based, non –inferiority phase III/ IV clinical study
STUDY AREA: OPD & IPD patients of NIMS hospital in department of Pediatrics
SAMPLE SIZE AND SAMPLING TECHNIQUE:
A total of 100 patients to be selected by Odd-Even Randomized sampling technique.(50 Cases in each arm)
STUDY POPULATION: Children between age 2-14 years.
STUDY PERIOD: Six Month for a case.
TIME FRAME: One Year
STASTICAL ANALYSIS: All Intragroup datas will be qualitative which will be calculated with Chi- Square test and Inter group datas will be quantitative where Unpare T test will be applicable, all datas will be plotted on SPSS 2.0 softwere
INCLUSION CRITERIA:
• Healthy children of either gender between 2-14 years of age .
• Subject in a good clinical condition as judged by the investigator based on medical history and physical examination
• Written informed consent obtained from the subject’s parents or legally acceptable representative
EXCLUSION CRITERIA:
• Age less than 2 years and more than 14 years.
• Children with associated conditions like hypothyroidism, celiac disease, Malnutrition, HIV, Malignancies and Acute or Chronic illnesses will be excluded.
METHODOLOGY: After enrollment of patient with all inclusion criteria , a odd even randamization will be applicable to the patient and two groups will be made onthe basis of drug intervention as allopathic and ayurvedic drug. After complettee treatment and follow up all results will be record.
Questionnaire for all patient:
1- Frequency to passing stool ?
a) Daily b) 2-4 days c) 5-7 days d) >7 Days
2-Consistency of stool ?
a) Liquid b) Semi solid c) Solid d) Hard
3- Feeling pain during passing stool ? Yes/No
4- Bleeding during passing stool ? Yes/No
5-Distension of abdomen ? Yes/No
INVESTIGATIONS
• At First Visit:
Blood investigations to rule out other associated disease ( If required)
CBC, LFT, Free T4, TSH, Ttg-IgA, HIV serology, Serum Electrolyte
• In Follow up Visit:
Serum electrolyte and others if required
研究设计
- 研究类型
- Interventional
- 分配方式
- Other
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 2.00 Year(s) 至 14.00 Year(s)(—)
- 性别
- All
入选标准
- •1-Healthy children of either gender between 2-14 years of age .
- •2-Subject in a good clinical condition as judged by the investigator based on 3-3-3-medical history and physical examination Written informed consent obtained from the subject’s parents or legally acceptable representative.
排除标准
- •1-Age less than 2 years and more than 14 years.
- •2-Children with associated conditions like hypothyroidism, celiac disease, Malnutrition, HIV, Malignancies and Acute or Chronic illnesses will be excluded.
结局指标
主要结局
Average change in passing Frequency & consistency of stool
时间窗: Visit 1: Day 0 – Baseline visit | Visit 2: Day 7 – First follow-up visit | Visit 3: One month – Second follow-up visit | Visit 4: Two month – Third follow-up visit | Visit 5: Three month– Fourth follow-up visit | Visit 6: Six Month – Fifth follow-up visit
Change in routine activity school going
时间窗: Visit 1: Day 0 – Baseline visit | Visit 2: Day 7 – First follow-up visit | Visit 3: One month – Second follow-up visit | Visit 4: Two month – Third follow-up visit | Visit 5: Three month– Fourth follow-up visit | Visit 6: Six Month – Fifth follow-up visit
次要结局
- Passing Blood / Pain/ Distension during trial(Find any abnormal investigation parameter during trial)
